Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drugs in R and D is Scopus-indexed (Q3, CiteScore 4), WoS SCIE, DOAJ. Published by Adis.
Checked against the index lists dated .
ISSN 1174-5886Verify ISSN ↗1179-6901Verify ISSN ↗
Publisher: Adis
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 183 / 328 | 44th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2010–present (also 2002–2008, 1999), best quartile Q3, CiteScore 4.
Drugs in R and D is Q3 in Pharmacology (rank 183 of 328), by CiteScore 2025.
Drugs in R and D is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4, which places it in quartile Q3 at the 44th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.918, quartile Q2, with an H-index of 58.
The publisher lists an article processing charge of about US$3,490 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Drugs in R and D is published by Adis. Its print ISSN is 1174-5886 and its online ISSN is 1179-6901.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Drugs in R and D has an h-index of 62 and a 2-year mean of 3.22 citations per paper (OpenAlex). Its Scopus CiteScore is 4, quartile Q3. On 2-year citations it ranks #107 of 319 Scopus journals in Pharmacology.
Drugs in R and D published 31 papers in 2025; its busiest recent year was 2017 with 61. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2023–2026), authors are most often from China (38.1%), United States (20.7%) and Germany (5.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.